SAGE

Sage Therapeutics, Inc.

11.79 USD
+0.01 (+0.08%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Sage Therapeutics, Inc. stock is down -13.88% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 Apr 18:28 16 Aug, 2024 22.50 CALL 650 663
24 Apr 14:55 17 May, 2024 12.50 PUT 500 371
24 Apr 17:35 21 Jun, 2024 12.50 CALL 500 2218
24 Apr 18:03 21 Jun, 2024 12.50 CALL 105 2218
26 Apr 14:28 21 Jun, 2024 12.50 CALL 475 2925
02 May 13:50 21 Jun, 2024 12.50 CALL 500 3602
13 May 17:33 21 Jun, 2024 12.50 CALL 362 4406
16 May 13:46 21 Jun, 2024 10.00 CALL 500 748
16 May 13:51 21 Jun, 2024 10.00 CALL 120 748
21 May 16:00 19 Jul, 2024 10.00 CALL 500 0

About Sage Therapeutics, Inc.

Sage Therapeutics, Inc. develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor.